Payment overview · 2025
General Payments
$469.97
21 reported records · 6 companies
Healthcare provider profile · identity verified
Blanche Leung, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1124082011
Verified facts
What the public records show
CMS Open Payments records show Blanche Leung, M.D. received $469.97 in general payments during 2025 across 21 reported records.
Sumitomo Pharma America, Inc. accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Prolia, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $214.80 | 45.7% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.23 | 13.2% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $58.85 | 12.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $54.91 | 11.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.54 | 11.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.64 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $469.97 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $199.68 | 10 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $54.91 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $53.54 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.61 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 20 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 377 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 75 |
| Losartan Potassium | Losartan Potassium | 227 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 59 |
| Raloxifene Hcl | Raloxifene Hcl | 211 | 48 |
| Simvastatin | Simvastatin | 156 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 122 | 32 |
| Metformin Hcl | Metformin Hcl | 118 | 36 |
| Alendronate Sodium | Alendronate Sodium | 111 | 37 |
| Ammonium Lactate | Ammonium Lactate | 67 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 14 |
| Vascepa | Icosapent Ethyl | 61 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 12 |
| Jardiance | Empagliflozin | 52 | 12 |
| Metformin Hcl Er | Metformin Hcl | 51 | 12 |
| Gabapentin | Gabapentin | 50 | 11 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 14 |
| Meloxicam | Meloxicam | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 14 |
| Lisinopril | Lisinopril | 45 | 11 |
| Celecoxib | Celecoxib | 40 | 11 |
| Furosemide | Furosemide | 38 | 15 |
| Famotidine | Famotidine | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Atenolol | Atenolol | 34 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Omeprazole | Omeprazole | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 21 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Prolia | Denosumab | 20 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $469.97 · 21 records | Sumitomo Pharma America, Inc. | DUPIXENT, EVENITY, GEMTESA, JARDIANCE, MYFEMBREE, OTEZLA, PROLIA, REPATHA, SYNTHROID | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error